Last updated: August 11, 2026
Triferic, ferric pyrophosphate citrate, is an iron-replacement product developed for patients receiving hemodialysis. Its commercial premise was differentiated: deliver iron continuously through the dialysate or intravenously during dialysis rather than through intermittent intravenous bolus dosing. The product obtained FDA approval, but commercial adoption remained limited relative to established intravenous iron products. Triferic’s financial contribution became immaterial within Akebia Therapeutics’ portfolio, and the company discontinued U.S. commercial operations for Triferic and Triferic AVNU at the end of 2021.[1][2]
The product’s principal market value was its clinical differentiation, not scale. Triferic faced entrenched competition from generic iron sucrose, ferric carboxymaltose, ferumoxytol, and other dialysis anemia treatments. Its patent estate provided protection around ferric pyrophosphate citrate compositions and dialysis administration methods, but did not overcome reimbursement, dialysis-provider purchasing behavior, and limited commercial execution.
What is Triferic and how does ferric pyrophosphate citrate work?
Triferic is ferric pyrophosphate citrate, an iron-replacement therapy for maintaining hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease.
The product was approved in two forms:
| Product |
FDA dosage form |
Administration |
Approval |
| Triferic |
Dialysate additive powder |
Added to bicarbonate concentrate used during hemodialysis |
2015 |
| Triferic AVNU |
Intravenous solution |
Administered through the dialysis circuit during hemodialysis |
2019 |
Triferic transfers iron directly through the dialysate or dialysis circuit. The intended pharmacologic distinction was delivery of iron during each dialysis session, matching ongoing iron loss and erythropoiesis requirements. Conventional dialysis iron products are generally administered intermittently through intravenous injection or infusion.
Triferic was developed to address functional iron deficiency and iron losses associated with hemodialysis. Its commercial positioning depended on reducing reliance on intermittent intravenous iron and integrating treatment into routine dialysis procedures.[3][4]
How does Triferic compare with conventional intravenous iron?
| Attribute |
Triferic |
Iron sucrose |
Ferric carboxymaltose |
Ferumoxytol |
| Active iron form |
Ferric pyrophosphate citrate |
Iron sucrose |
Ferric carboxymaltose |
Ferumoxytol |
| Primary dialysis use |
Hemodialysis patients |
Broad CKD and dialysis use |
Broad CKD use |
CKD and iron-deficiency anemia |
| Delivery |
Dialysate or dialysis circuit |
IV injection or infusion |
IV infusion |
IV infusion |
| Dosing concept |
Continuous or per-session iron delivery |
Intermittent dosing |
Larger replacement doses |
Usually two-dose replacement |
| Generic competition |
Limited direct competition |
Established generic competition |
Patent and market competition |
Generic competition emerged |
| Operational model |
Requires dialysis-center integration |
Familiar IV workflow |
Infusion workflow |
Infusion workflow |
Triferic’s delivery model was clinically distinctive but operationally demanding. Dialysis providers had to incorporate the product into existing supply, dosing, and treatment protocols. That requirement reduced the advantage of the product’s delivery mechanism in a market where established injectable iron products were familiar and widely available.
When did Triferic lose exclusivity and commercial momentum?
Triferic’s practical commercial exclusivity ended before its patent estate became irrelevant. The product did not develop into a large independent revenue stream, and Akebia stopped commercializing it in the United States effective December 31, 2021.[2]
The key timeline is:
| Date |
Event |
| 2015 |
FDA approved Triferic dialysate formulation for hemodialysis patients |
| 2018 |
Akebia completed its merger with Keryx Biopharmaceuticals and acquired Keryx’s products, including Auryxia and Triferic |
| 2019 |
FDA approved Triferic AVNU, an intravenous formulation |
| 2020 |
Akebia operated Triferic and Triferic AVNU within a portfolio increasingly centered on Auryxia and pipeline assets |
| 2021 |
Akebia announced discontinuation of U.S. commercial operations for Triferic and Triferic AVNU |
| December 31, 2021 |
U.S. commercial availability ended |
| 2022 onward |
Akebia’s financial disclosures focused on Auryxia, vadadustat development, and later Vafseo rather than Triferic revenue |
The commercial discontinuation is more important than a simple patent-expiration analysis. Triferic did not require a large generic erosion event to lose market relevance. The product’s economic decline reflected limited adoption, reimbursement constraints, and portfolio prioritization.
What patents protect Triferic?
Triferic’s intellectual-property position centers on ferric pyrophosphate citrate compositions, manufacturing methods, and methods of delivering iron during dialysis.
Publicly associated U.S. patent families include patents directed to ferric pyrophosphate citrate compositions and dialysis use. Patent scope and expiration depend on the specific patent, terminal disclaimers, patent-term adjustment, and Orange Book listing status. The principal patent families associated with the product include:
| Patent or family |
General subject matter |
Strategic relevance |
| U.S. Patent No. 8,318,202 |
Ferric pyrophosphate citrate compositions and related uses |
Core composition and product protection |
| U.S. Patent No. 9,101,641 |
Ferric pyrophosphate citrate formulations and administration |
Supplemental formulation or use protection |
| Related continuation families |
Dialysis delivery, formulation, and manufacturing claims |
Potential barriers to direct substitution |
Patent numbers and expiration dates should be read against the FDA Orange Book and USPTO records for the relevant product listing. A patent covering the active ingredient or a broad composition does not automatically prevent all alternative iron products. Generic or follow-on competitors may design around claims by using a different iron complex, formulation, concentration, or administration route.
What formulations are protected by Triferic patents?
The product’s patent strategy was built around more than the chemical identity of ferric pyrophosphate citrate. Relevant claim categories included:
- Ferric pyrophosphate citrate compositions.
- Stable aqueous or concentrated formulations.
- Powder formulations suitable for incorporation into dialysis concentrate.
- Methods for delivering iron during hemodialysis.
- Manufacturing and storage conditions designed to preserve product stability.
- Intravenous administration through the dialysis circuit.
This structure can create a layered barrier, but the protection is commercially useful only if the protected formulation is used by a competitor. A generic injectable iron product based on iron sucrose or ferric carboxymaltose would not necessarily infringe Triferic composition claims.
What is the Orange Book status of Triferic?
Triferic was approved through the FDA’s new-drug application pathway rather than as a generic product. The FDA listed Triferic and Triferic AVNU in Drugs@FDA materials, with the approved labeling identifying ferric pyrophosphate citrate as the active ingredient.[3][4]
The Orange Book implications are more limited than for a high-revenue chronic medicine:
- Triferic was a small-molecule product, so an ANDA pathway could apply to a qualifying generic competitor.
- Triferic was not a biologic, so biosimilar litigation under the Public Health Service Act is not the relevant framework.
- Any listed patents could support Paragraph IV litigation if an ANDA applicant alleged noninfringement, invalidity, or unenforceability.
- Discontinuation of commercial sales does not automatically eliminate all patent rights.
- FDA regulatory discontinuation and patent expiration are separate events.
The product’s commercial discontinuation also reduces the incentive for a generic manufacturer to invest in an ANDA, clinical bridging work, manufacturing scale-up, and dialysis-provider conversion.
Were there Paragraph IV challenges to Triferic?
No major, publicly prominent Paragraph IV campaign against Triferic is identified in the principal FDA and company disclosures through the product’s U.S. commercial discontinuation.
That outcome is commercially rational. Paragraph IV litigation is most attractive when the branded product has substantial sales, a clear generic substitution pathway, and enough remaining market life to support litigation costs. Triferic had none of those characteristics at scale by the end of its commercial period.
The absence of a prominent Paragraph IV challenge does not mean the patents were necessarily strong. It more likely indicates that the expected market opportunity was insufficient to justify a challenge. Patent strength and patent value diverged:
| Measure |
Triferic assessment |
| Composition protection |
Potentially meaningful for direct ferric pyrophosphate citrate copies |
| Formulation protection |
Relevant to matching Triferic’s dialysate or IV presentation |
| Method-of-use protection |
Narrower because dialysis iron treatment has several alternatives |
| Generic incentive |
Low after U.S. discontinuation |
| Litigation risk |
Limited by the small commercial opportunity |
| Patent value |
Higher as a defensive asset than as a revenue-generating asset |
What was Triferic’s financial trajectory?
Akebia did not consistently report Triferic revenue as a separately material line item in its public financial statements. Revenue disclosures emphasized the combined commercial portfolio, especially Auryxia, while Triferic was described as a smaller product.
The financial trajectory can be summarized as follows:
| Period |
Financial position |
| 2015-2017 |
Early commercialization with limited penetration in the dialysis market |
| 2018 |
Acquired by Akebia through the Keryx merger; product value became part of a broader renal portfolio |
| 2019-2020 |
Triferic AVNU expanded the product platform but did not produce a material shift in portfolio economics |
| 2021 |
Commercial discontinuation reflected limited market scale and portfolio prioritization |
| 2022 onward |
No meaningful Triferic revenue contribution in Akebia’s strategic focus |
Triferic’s weak financial trajectory resulted from several interacting factors.
Reimbursement limited adoption
Dialysis providers operate under tightly managed reimbursement and procurement systems. A product that adds a new administration process must demonstrate a clear economic benefit, not only a pharmacologic difference. Triferic’s value proposition depended on reducing episodic intravenous iron use, but providers also had to absorb the cost of the product, training, inventory, and workflow changes.
Generic iron created price pressure
Generic iron sucrose had a strong position in dialysis. Products such as Venofer and generic iron sucrose offered providers a familiar, reimbursed, and operationally established treatment. Even when Triferic offered a differentiated dosing model, the price and procurement advantages of generic products constrained conversion.
The product required center-level adoption
Triferic’s dialysate presentation required adoption by dialysis organizations and treatment centers. This created a concentrated sales challenge. Winning individual prescribers was less important than obtaining institutional approval and standardizing use across dialysis facilities.
Akebia prioritized higher-value assets
After the Keryx transaction, Akebia’s commercial strategy centered on Auryxia and its hypoxia-inducible factor prolyl hydroxylase inhibitor program. Triferic was a smaller asset with limited growth potential. Maintaining sales infrastructure for a low-revenue product was difficult to justify against development and commercialization needs elsewhere in the portfolio.[1][2]
Which companies challenged Triferic in the dialysis iron market?
Triferic competed against products from several manufacturers rather than against one direct generic equivalent.
| Company |
Competing product or category |
Competitive effect |
| Fresenius Medical Care |
Venofer and dialysis-center infrastructure |
Strong dialysis-channel presence |
| Generic manufacturers |
Iron sucrose |
Low-cost substitution pressure |
| American Regent and other suppliers |
IV iron products |
Established provider familiarity |
| Daiichi Sankyo |
Injectafer, ferric carboxymaltose |
Larger-dose iron replacement |
| Covis Pharma and other suppliers |
Monoferric, ferric derisomaltose |
Alternative high-dose IV iron |
| Fera Pharmaceuticals |
Feraheme, ferumoxytol |
Alternative IV iron for CKD and iron deficiency |
The most important competitive threat was generic iron sucrose, not a direct ferric pyrophosphate citrate copy. Triferic had to change provider behavior in a market where the incumbent treatment category already had multiple low-cost options.
What generic entry risks exist for Triferic?
Direct generic entry risk is currently secondary to product discontinuation risk.
A potential ANDA applicant would face several barriers:
- Limited commercial demand following U.S. withdrawal.
- Need to match the relevant route and dosage form.
- Possible formulation and stability differences.
- Need to establish pharmaceutical equivalence.
- Dialysis-center conversion requirements.
- Uncertain reimbursement economics.
- Patent claims covering specific ferric pyrophosphate citrate formulations or methods.
A competitor could instead pursue a different strategy: develop another iron product for dialysis using a different active ingredient and rely on existing clinical and regulatory pathways. That approach would avoid direct infringement risk but would compete with Triferic’s original market concept.
Does Triferic face biosimilar risk?
No. Triferic is a small-molecule drug, not a biologic. The relevant competitive pathway is an ANDA or, depending on the product design, a new 505(b)(2) application. Biosimilar approval under the Biologics Price Competition and Innovation Act is not applicable.
A 505(b)(2) competitor could seek approval for an alternative formulation or route using existing safety and efficacy information while introducing differences from the reference product. Such a product could create more meaningful competition than a conventional generic if it offered simpler dialysis-center administration or improved reimbursement.
What litigation and settlement agreements affect Triferic?
No major publicly reported patent settlement involving Triferic is central to its market history through the end of its U.S. commercial period. The absence of a reported settlement is consistent with the product’s limited sales and lack of a significant generic challenge.
The most important legal event was corporate rather than patent-related: Akebia’s 2018 merger with Keryx transferred control of Triferic and related commercial assets to Akebia.[1] The transaction changed portfolio ownership but did not create a large new commercial platform for Triferic.
How strong is the Triferic patent estate?
The patent estate was technically meaningful but commercially moderate.
Its strongest elements were likely the claims closest to the product’s specific ferric pyrophosphate citrate composition and the formulation used for dialysis delivery. Its weaker elements were broader method-of-use claims that competed against multiple alternative iron formulations.
Patent strength should be assessed across four dimensions:
- Claim breadth. Narrow claims to a specific composition provide strong protection against exact copies but limited protection against alternative iron complexes.
- Remaining term. Patent term matters only if the product has enough market demand to support enforcement.
- Design-around potential. Competing iron products can use different chemical entities or dosing systems.
- Commercial enforceability. Low sales reduce the economic value of patent litigation.
For Triferic, patent protection did not translate into durable market power. The principal constraint was product economics, not a demonstrated collapse caused by invalidity or infringement litigation.
What is Triferic’s geographic coverage?
Triferic’s principal commercial and regulatory significance was in the United States. Akebia’s public strategy and product disclosures focused on the U.S. dialysis market. The product did not develop into a major global commercial franchise comparable to large multinational anemia or iron products.
Geographic value was limited by:
- Country-specific dialysis reimbursement systems.
- Local approval requirements.
- Different standards for dialysate additives and dialysis-center procurement.
- Competition from locally available injectable iron products.
- The need to negotiate with concentrated dialysis providers.
The United States had the clearest commercial opportunity because of its large dialysis population and established dialysis-provider infrastructure. It also had the strongest generic and reimbursement pressure.
What manufacturing and intellectual-property barriers affect Triferic?
Manufacturing ferric pyrophosphate citrate for dialysis use requires control of chemical stability, concentration, compatibility, and storage. The dialysate formulation adds manufacturing and quality requirements beyond those for a conventional injectable iron product.
Potential barriers include:
- Maintaining product stability in powder or concentrated form.
- Controlling iron speciation and release characteristics.
- Ensuring compatibility with bicarbonate concentrate and dialysis equipment.
- Validating sterile manufacturing for the AVNU product.
- Demonstrating consistent dosing across dialysis sessions.
- Establishing supply reliability for dialysis-center use.
These barriers may deter small competitors, but they do not create a durable moat if market demand is low. Manufacturing complexity has value only when the resulting product achieves sufficient price and volume.
What is Triferic’s future commercial outlook?
Triferic has limited standalone commercial prospects in the United States because Akebia discontinued U.S. commercialization in 2021. The product’s remaining strategic value is more likely to reside in intellectual property, clinical know-how, or potential licensing than in direct revenue.
A revival would require a new commercial owner, renewed manufacturing and distribution, a clear reimbursement strategy, and evidence that dialysis providers would adopt the product over low-cost intravenous iron. Those requirements make a broad relaunch unlikely without a focused partner or a new contractual model with large dialysis organizations.
The more realistic value scenarios are:
| Scenario |
Commercial probability |
Value driver |
| U.S. relaunch of original products |
Low |
Requires substantial infrastructure rebuilding |
| Licensing of patents or formulation know-how |
Moderate but uncertain |
Defensive or platform value |
| Direct generic launch |
Low |
Limited post-discontinuation demand |
| 505(b)(2) reformulation |
Low to moderate |
Could improve workflow or reimbursement |
| No further material commercialization |
High |
Consistent with the 2021 withdrawal |
Key Takeaways
- Triferic is ferric pyrophosphate citrate, an iron-replacement product for hemodialysis patients.
- FDA approved the dialysate formulation in 2015 and Triferic AVNU in 2019.
- Akebia discontinued U.S. commercial operations for Triferic and Triferic AVNU effective December 31, 2021.
- Triferic did not become a material standalone revenue contributor in Akebia’s portfolio.
- Generic iron sucrose and established IV iron products were the primary commercial threats.
- The product is a small molecule, so generic and 505(b)(2) pathways matter; biosimilar risk does not.
- Its patent estate protected ferric pyrophosphate citrate compositions, formulations, and dialysis-use methods, but commercial value was limited by low market adoption.
- No major publicly reported Paragraph IV litigation or patent settlement drove Triferic’s market decline.
- Triferic’s remaining value is primarily defensive or licensing-related rather than revenue-based.
FAQs About Triferic Patents, Revenue, and Market Competition
Is Triferic still sold in the United States?
No. Akebia discontinued U.S. commercial operations for Triferic and Triferic AVNU effective December 31, 2021.[2]
Is Triferic the same as Venofer?
No. Triferic contains ferric pyrophosphate citrate. Venofer contains iron sucrose. They are different iron products with different formulations and administration strategies.
Can a generic company file an ANDA for Triferic?
Potentially. Triferic is a small-molecule drug, so an ANDA could be relevant if a manufacturer can establish pharmaceutical equivalence. The commercial incentive is limited because the branded product is no longer actively commercialized in the United States.
Did Triferic generate material revenue for Akebia?
No material standalone revenue stream was reported. Akebia’s commercial disclosures emphasized Auryxia and other strategic assets rather than Triferic.
Was Triferic protected by biologic exclusivity?
No. Triferic is not a biologic and was not protected by the biosimilar exclusivity framework. Its protection depended on small-molecule regulatory exclusivity, listed patents, formulation know-how, and clinical data.
References
-
Akebia Therapeutics, Inc. (2018). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934: Form 10-K for fiscal year ended December 31, 2018. U.S. Securities and Exchange Commission.
-
Akebia Therapeutics, Inc. (2021). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934: Form 10-K for fiscal year ended December 31, 2021. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2015). Triferic ferric pyrophosphate citrate: Prescribing information and approval history. Drugs@FDA.
-
U.S. Food and Drug Administration. (2019). Triferic AVNU ferric pyrophosphate citrate: Prescribing information and approval history. Drugs@FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
-
U.S. Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records for ferric pyrophosphate citrate patent families. U.S. Department of Commerce.
